<DOC>
	<DOCNO>NCT02460146</DOCNO>
	<brief_summary>The main purpose trial demonstrate safety , tolerability pharmacokinetics ( PK ) CXA-10 metabolite ( ) administer multiple ascend oral dos 14 day healthy obese male volunteer .</brief_summary>
	<brief_title>PK PD Sequential Multiple Ascending , Repeat Doses Oral CXA-10 Healthy Obese Male Subjects</brief_title>
	<detailed_description>Complexa develop oral formulation CXA-10 . The main purpose trial demonstrate safety , tolerability pharmacokinetics ( PK ) CXA-10 metabolite ( ) administer multiple ascend oral dos 14 day healthy obese male volunteer . The pharmacodynamic ( PD ) effect CXA-10 serum biomarkers , elevate obese population , also investigate .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>Body mass index ( BMI ) &gt; 27 ≤40 kg/m2 In good general health determine thorough medical history physical examination , ECG , vital sign , clinical laboratory evaluation Results clinical laboratory test must without clinically significant abnormality population may exceed limit reference range , include hematology , clinical chemistry urinalysis except noted Hemoglobin A1c ( HbA1c ) &lt; 7 % Average blood pressure &lt; 160/100 mmHg screen QTcF interval ( Fredericia 's correction factor ) must ≤430 msec screen predose Any clinically relevant abnormality population identify screen history , physical laboratory examination , medical condition circumstance make volunteer unsuitable participation study Any clinical history cardiovascular event , arrhythmia , fainting , palpitation , personal family history congenital prolong QT syndrome sudden unexpected death due cardiac reason History primary malignancy , include history melanoma suspicious undiagnosed skin lesion , exception basal cell squamous cell carcinoma skin cervical carcinoma situ malignancy curatively treat evidence disease least 5 year History regular alcohol consumption exceed 21 units/week ( one unit = 125 mL wine 284 mL beer single 25 mL measure spirit ) within 6 month screen Treatment prescription nonprescription drug ( include vitamin , herbal dietary supplement ) within 7 day 5 halflives , whichever longer , prior dose collection final PK sample . Use drug include aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) must avoid within 7 day prior first dose study may interfere pharmacology CXA10 . Use high energy supplement drink ( especially , contain caffeine , protein supplement , weight loss drug ) History smoking , include ecigarettes , use nicotinecontaining product within 1 month screen Resting heart rate ≥100 BPM 5 minute rest ( ) screen visit Subjects clinically relevant ECG parameter abnormality ( e.g. , PR interval , QRS deviation ) clinically significant ECG abnormality exclude study Any clinically significant murmur evident auscultation heart ( include evidence mitral valve prolapse )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>